The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
A novel oral microtubule inhibitor utidelone capsule (UTD2): A phase 1 clinical study to assess the tolerability, safety, and efficacy in advanced solid tumors.
 
Judy S. Wang
Consulting or Advisory Role - Fusion Pharmaceuticals; Kanaph Therapeutics
Speakers' Bureau - AstraZeneca; Eisai
Research Funding - Accutar Biotech (Inst); Adagene (Inst); Agenus (Inst); Allorion Therapeutics (Inst); Artios (Inst); Astellas Pharma (Inst); AstraZeneca (Inst); Bayer Health (Inst); BeiGene (Inst); Bicycle Therapeutics (Inst); BioNTech (Inst); Biostar (Inst); BioTheryX (Inst); Blueprint Medicines (Inst); BMS GmbH & Co. KG (Inst); Boehringer Ingelheim (Inst); C4 Therapeutics (Inst); Celgene (Inst); Centessa Pharmaceuticals (Inst); Coherus Biosciences (Inst); Compugen (Inst); Cullinan Oncology (Inst); cyteir (Inst); Daiichi Sankyo (Inst); Ellipses Pharma (Inst); Erasca, Inc (Inst); Forty Seven (Inst); Genentech/Roche (Inst); Georgiamune (Inst); GlaxoSmithKline (Inst); H3 Biomedicine (Inst); Hotspot Therapeutics (Inst); IgM Biosciences (Inst); Immune-Onc Therapeutics (Inst); Immunitas (Inst); Immunogen (Inst); Janssen Research & Development (Inst); Jazz Pharmaceuticals (Inst); Kineta (Inst); Klus Pharma (Inst); Kura Oncology (Inst); Kymab (Inst); Loxo (Inst); LSK BioPharma (Inst); MabSpace Biosciences (Inst); Macrogenics (Inst); Medikine (Inst); Merck (Inst); Mersana (Inst); Moderna Therapeutics (Inst); NGM Biopharmaceuticals (Inst); Nurix (Inst); Olema Oncology (Inst); Phoenix Pharmaceuticals (Inst); Prelude Therapeutics (Inst); PureTech (Inst); Pyxis (Inst); QiLu Pharmaceutical (Inst); Relay Therapeutics (Inst); Revolution Medicines (Inst); Ribon Therapeutics (Inst); Sanofi (Inst); Seven and Eight Biopharmaceuticals (Inst); Step Pharma (Inst); Syndax (Inst); Tango Therapeutics (Inst); TeneoBio (Inst); Treadwell Therapeutics (Inst); Vividion Therapeutics (Inst); Xencor (Inst); Zymeworks (Inst)
 
Brian Andrew Van Tine
Leadership - Polaris
Honoraria - Iterion Therapeutics, Inc; Total Health Conference
Consulting or Advisory Role - Aadi; Acuta Capital Partners, LLC; ADRx; Advenchen Laboratories; Agenus; Ayala Pharmaceuticals; Bayer; Boehringer Ingelheim; Boxer Capital LLC; Curis; Daiihi Sankyo; Deciphera; Deciphera Pharmaceuticals,; EcoR1 Capital; Epizyme; Hinge Bio, Inc.; Intellisphere; Kronos Bio, Inc.; PTC Therapeutics; PTC Therapeutics; Putnam Associates; Race Oncology; Regeneron; Salarius Pharmaceuticals, Inc.,
Research Funding - GlaxoSmithKline; Merck; Pfizer; Polaris; TRACON Pharma
Patents, Royalties, Other Intellectual Property - Accuronix Therapeutics- Licensing agreement. Sigma-2 Receptor Ligands and Therapeutic uses therefor (006766), • Modular Platform for Targeted Therapeutic Delivery (006755), • Sigma-2 Receptor Ligand Drug Conjugates as Antitumor Compounds, Methods of synth; Patent on ALEXT3102; Patent on the use of ME1 as a biomarker
Expert Testimony - Health Advances
Travel, Accommodations, Expenses - Adaptimmune; Advenchen Laboratories; Kronos Bio, Inc
 
Manish R. Patel
Leadership - ION Pharma
Honoraria - Janssen Oncology
Consulting or Advisory Role - Accutar Biotech; Daiichi Sankyo/UCB Japan; Kura Oncology; Olema Pharmaceuticals
Research Funding - Accutar Biotech (Inst); Accutar Biotech (Inst); Acerta Pharma (Inst); Adagene (Inst); ADC Therapeutics (Inst); Agenus (Inst); Allorion Therapeutics (Inst); Artios (Inst); Artios (Inst); Artios (Inst); Artios (Inst); Astellas Pharma (Inst); AstraZeneca (Inst); BioNTech (Inst); BioTheryX (Inst); BioTheryX (Inst); Blueprint Medicines (Inst); Boehringer Ingelheim (Inst); Bristol-Myers Squibb/Celgene (Inst); Celgene (Inst); Compugen (Inst); Compugen (Inst); Conjupro Biotherapeutics (Inst); Cullinan Oncology (Inst); cyteir (Inst); Daiichi Sankyo (Inst); Erasca, Inc (Inst); Genentech/Roche (Inst); Georgiamune (Inst); Gilead Sciences (Inst); GlaxoSmithKline (Inst); H3 Biomedicine (Inst); Hengrui Therapeutics (Inst); Hotspot Therapeutics (Inst); Hutchison MediPharma (Inst); Immune-Onc Therapeutics (Inst); Immunitas (Inst); Immunogen (Inst); Incyte (Inst); Janssen (Inst); Kineta (Inst); Klus Pharma (Inst); Kura Oncology (Inst); Kymab (Inst); Lilly (Inst); Loxo (Inst); LSK BioPharma (Inst); MabSpace Biosciences (Inst); MabSpace Biosciences (Inst); Macrogenics (Inst); Merck (Inst); Millennium (Inst); Moderna Therapeutics (Inst); Novartis (Inst); Novartis (Inst); Novartis (Inst); Nurix (Inst); nurix (Inst); Olema Oncology (Inst); ORIC Pharmaceuticals (Inst); ORIC Pharmaceuticals (Inst); Pfizer (Inst); Pionyr (Inst); Prelude Therapeutics (Inst); PureTech (Inst); PureTech (Inst); Puretech (Inst); Ribon Therapeutics (Inst); Ribon Therapeutics (Inst); Seven and Eight Biopharmaceuticals (Inst); Step Pharma (Inst); Syndax (Inst); Syndax (Inst); Taiho Pharmaceutical (Inst); TeneoBio (Inst); Tesaro (Inst); Treadwell Therapeutics (Inst); Treadwell Therapeutics (Inst); Vividion Therapeutics (Inst); Zymeworks (Inst)
 
Diana L. Hanna
Consulting or Advisory Role - AstraZeneca; Boehringer Ingelheim
Research Funding - Agenus (Inst); Dragonfly Therapeutics (Inst); Indaptus Therapeutics (Inst); Toray Industries (Inst); Xilio Therapeutics (Inst)
 
Li Tang
Employment - Biostar Pharma, Inc.
Leadership - Biostar Pharma, Inc.
Stock and Other Ownership Interests - Biostar Pharma, Inc.
Honoraria - Biostar Pharma, Inc.
Patents, Royalties, Other Intellectual Property - Biostar Pharma, Inc.
 
Rongguo Qiu
Employment - Biostar Pharma, Inc.
Leadership - Biostar Pharma, Inc.
Honoraria - Biostar Pharma, Inc.
Patents, Royalties, Other Intellectual Property - Biostar Pharma, Inc.
 
Jin Guan
Employment - Biostar Pharma, Inc.
Leadership - Biostar Pharma, Inc.
Honoraria - Biostar Pharma, Inc.
 
Jacob Stephen Thomas
Consulting or Advisory Role - Kura Oncology; Tasly Pharmaceuticals